When health becomes personalizedThe advent of precision or personalized medicine is introducing ‘individuality’ in the world of health. Precision medicine works in contrast to the ‘one-size-fits-all’…
Collective consensus – by engaging stakeholders in deliberative discussions, integrating ideas from structured dialogues, and with sustained stakeholder engagement processes – can pave the way to better solutions.
The phamax ad-board services provide independent strategic advice to steer companies on the right track and define the best development path for products. phamax addresses multifaceted challenges by tailoring its associations as per each organization’s objectives, market and culture by merging best research practices with hands-on support from its experts.
The phamax ad-board services develop an advisory board, expert group or panel as per the needs of its massive stakeholder network to guide in the development phase, therapeutic area, regulatory review preparation etc. The services:
We transform disaggregated information on markets and competitors into actionable insights. We combine secondary and primary research to derive information as per project objectives and scope. Our team continuously tracks the key parameters, provides regular updates (monthly/quarterly/half-yearly), develops key intelligence questions, and builds customized reports to meet specific requirements.
phamax’s structured and comprehensive CI package supports pharma companies in effective strategic, tactical and operational decisions to:
We determine the optimal price range for products by assessing the relevant internal and external factors. We support pharmaceutical companies in effective pricing decisions using analytical modeling to decrypt the real-world complexities.
Our price mapping services:
Health technology assessments (HTA) to reimburse a new health technology typically encompass an economic analysis. Pharmaceutical manufacturers must demonstrate the clinical and economic evidences of products to gain market access and remain competitive. Economic evidence is often generated by evaluating both costs and outcomes to prove the efficiency of a product. phamax HEOR services generate relevant evidence for products to communicate their value to stakeholders.
phamax HEOR services include:
phamax PRO studies provide unique insights into how a therapy can affect a patient. We design studies that enable clients to capture patient perspectives on a disease/treatment under different scenarios – clinical (e.g. cure, survival), humanistic (e.g. role performance, emotional status) and economical (e.g. expenses, saving)
Our models estimate the costs and outcomes of interventions, and compare different interventions impacting the same health effects (usually measured as life years gained) and different health effects (usually measured as utility-based outcome units (QALYs)). HEOR models for economic evaluations are the new normal for favourable reimbursement decisions. Our services demonstrate the cost effectiveness of product vs. the competition to support reimbursement submissions and highlight the incremental effectiveness of products at multiple price points.
The phamax white paper services generate authoritative and compelling reports for information on complex issues in therapeutic areas of focus. phamax generates credible information by combining expert knowledge and research to share relevant information on customers, potential customer bases and the latest industry trends.
phamax offers unparalleled commitment and quality to develop influential vantage point white papers which garner useful information about new products, markets or ways to re-hash obsolete data. We empower companies with the confidence to broadcast their products and solutions worldwide with the trustworthy information we create.
Our white paper services use:
phamax reviews the existing KAM structure and analyses the account-level data for robustness/integrity to identify the gaps, provide appropriate solutions based on customer needs and develop KAM as a mind-set. We help our clients in developing the best-in- class strategy, customized account-level services, optimal KAM team structure and thereby increased ROIs.
Our KAM framework utilizes:
We develop a prioritized list of recommendations and a corresponding action plan based on the qualitative and quantitative research.
The phamax scientific platform communicates a single vision for goals across multiple channels and stakeholders. phamax is a recognized leader in scientific communication platforms. We have presented original research, given invited presentations and conducted workshops at various scientific meetings. Our teams are extensively experienced in developing scientific platforms for almost any situation for de novo and top pharmaceutical companies.
Sustain and implement the best protocols and guidelines in routine practice
The phamax real-world evidence solutions empower the RWE strategies of companies with a deeper understanding of therapeutic landscapes and market-shaping dynamics. The phamax patient chart review services give pharmaceutical companies advanced inputs on the existing standards of care, healthcare resource utilization and patient-reported outcomes.
The phamax RWE division provides supporting evidence for a broad range of therapeutic areas. The phamax chart review services are widely applied in many healthcare-based disciplines such as epidemiology, quality assessment, professional education and residency training, inpatient care and clinical research.
Our patient chart review services use:
Discover the unattended patient segments and access untapped markets by visualizing patient movements. Understand treatment perceptions and physician preferences via the phamax patient journey models.
The phamax patient journey offering is a proven, proprietary and solution-oriented three-pronged approach tested and validated across multiple therapy areas and companies.
A – Analyze the real-world scenarios to develop a detailed patient journey to identify hidden patient segments and barriers to access /growth drivers
E– Review the drivers and barriers with all the stakeholders to successfully expand to new segments. Prioritize the segments and develop an action plan
A – Unlock growth potential by strategically implementing the business plan at the local levels with insights from the patient journey
Make the critical decision of ‘launch or license’ with our entry and expansion support. Our team supports all pharmaceutical commercialization activities – shaping your market entry or expansion strategies with relevant market insights or launching your products in new markets. The phamax comprehensive commercial model evaluation approach helps you formulate robust market entry strategies.
Our local team of experts not only design but implement the strategies. The phamax range of services include:
Foresee market evolutions and product opportunities with the phamax forecasting services. Plan your business better by predicting overall revenues, understanding physician preferences and comprehending relevant market trends with our robust forecast models.
The phamax suite of forecasting services is either custom built as per your needs or comes in a ready-to-use format.
Our forecasting services use:
Our services help companies manage risks and unlock value by engaging effectively with regulators, policymakers, and other external stakeholders. phamax assesses commercial, clinical and market-specific regulatory factors for crucial insights on market dynamics and evolution vital to address payer expectations and secure favorable reimbursement status.
The phamax regulatory assessment uses three customizable dimensions:
We simplify reporting processes, making regulatory filings less demanding. We provide country-specific regulatory landscape reports using the phamax scientific network with inputs from the local regulatory systems and stakeholders. Our solutions help companies comply with the local, regional and global regulatory requirements impacting products.
The phamax regulatory services:
– Understand the regulatory landscape to answer the KIQs on:
– The realistic view of the market and product potential as per the core regulatory assessment principles
– Understand the impact of the changing market environment on the ever-changing regulatory guidelines
– Choose the right scenario from multiple options
Epidemiological assessment identifies the relations between the needs and demands in the expansion of pharmaceutical and biological products. The phamax epidemiology assessment services help understand the market potential and identify the target patient segments. phamax develops an in-depth understanding of the disease landscape with scientifically-validated epidemiological analysis and forecast models.
phamax does an in-depth epidemiological analysis of therapeutic areas with primary and secondary research, real-world data and therapy-area expertise. Our scientific team includes experienced pharmaco-epidemiologists, physicians and biostatisticians. The team brings a broad range of scientific and operational experience while building forecasting models to accurately predict various epidemiological parameters such as incidence, prevalence, mortality, diagnosed population, treatment population, disease staging, risk-factors, related costs and medical management by age groups and sex. Our transparent and validated forecast models evaluating epidemiological transition and geographical extrapolation benefit global coverage.
The phamax epidemiological assessment services include:
phamax offers scientific writing services across the entire clinical research spectrum and is an expert in publications and medical communications services for global clients across all geographies.
Our team comprises writers with advanced degrees in medicine and other branches of life sciences. We have published various scientific publications in esteemed international journals. We have a wide range of research and clinical experience in multiple therapeutic areas like cardiovascular, medical devices, endocrinology, gastroenterology, hematology, oncology, orthopedics, respiratory, rheumatology, and urology.
The phamax medical writing services include a wide range of scientific and medical documentation ranging from manuscript writing for various research studies to regulatory submissions and medical communications documents such as:
We maximize returns from mature products by identifying the optimal resource allocation and portfolio strategy. We identify the most attractive products for strategic focus and less attractive products for divestment with our extensive experience and comprehensive framework.
Our portfolio evaluation services:
phamax offers a 360⁰ view of the competitor landscape with clinical, commercial and market access evaluations including, but not limited to, market drivers, existing and future therapies, unmet needs, disease burdens, and product potential. The phamax framework integrates clinical and commercial outputs to provide an in-depth understanding of market opportunities.
phamax offers a structured approach to understand and define the market opportunities as per needs:
Manage your business effectively with the phamax range of business intelligence services
Our solution experts have extensive experience in designing, building and maintaining tailor-made dashboards. The highly flexible models adapt to your dynamic business needs and supply what you need, when you need it, the way you need it.
phamax identifies KOLs via need assessment tools to offer customized solutions. Our robust approach identifies, prioritizes, segments and validates KOLs with in-depth secondary research. We combine qualitative and quantitative research as per various KOL activities – publications, congress presentations, clinical trials, guidelines, committees, editorial boards, company affiliations, regulatory bodies, associations and advocacy groups. We further profile the KOLs – demographics, memberships and roles in societies, abstracts of major publications, presentations and involvement in clinical trials.
phamax offers multiple KOL services:
Our KOL services:
